evaluation of the correlation of the vasculature resulted in a median of 5 [4;5]/5. CONCLUSIONS: Our 3D-models are accurate to the anatomical reality. We need quality assurance protocols like this, with radiologists, to enable appropriate medical practice regarding 3D printing. Evaluation of security of surgical assistance with 3D printed models comes next.
INTRODUCTION AND OBJECTIVES: Despite attempts to improve tumor response assessment, progression free survival (PFS) based on RECIST 1.1 (R1.1) is still the most common accepted primary endpoint for Phase 3 trials in renal cell carcinoma (RCC). Guidelines to assess tumor response based on changes in target lesions (TG) are quantifiable and established, but those used to assess tumor response based on non-target (NT) or new lesions (NL) are qualitative and subject to inter-observer variation. The purpose of our study was to retrospectively assess the most common criteria for determination of radiological progression (PD) assessed using R1.1 and how and how these criteria impact PFS.
METHODS: We conducted a secondary analysis of a cohort of patients enrolled in the METEOR trial who were randomized 1:1 to open label anti-VEGFR tyrosine kinase inhibitor (TKI) therapies. All patients had previously progressed after having received prior VEGFR TKI therapy and had ! 1 TG lesion at screening (SCR). A scan of the chest, abdomen and pelvis were acquired at SCR and every 8 weeks and interpreted by an independent review committee for PD using R1.1. PFS was compared using the Log-rank test and Kaplan-Meier curves were plotted. Median PFS (mPFS) was reported for each R1.1 measurement assessment.
RESULTS: We analyzed 395 subjects with a mean age of 60.7 years (SD AE 10.0). The mean number of follow-up visits was 4.9 (SDAE1.8) with a mean of 6.59 (SD AE 3.70) months enrolled. As summarized in Figure 1a , a significant difference (p<.0001) in PFS was observed in the 126 (32%) subjects where growth of TG alone determined PD (mPFS 5.44 months, IQR 3.87) compared to the 105 (27%) subjects where appearance of a NL in the 105 (27%) subjects (mPFS 3.61 months, IQR 3.60)] or to the 73(18%) subjects in whom unequivocal progression of a NT lesion (mPFS 2.79 months, IQR 3.54) defined PD. As summarized in Figure 1b , the remaining subjects had PD determined by a combination of assessments and no significant differences in PFS were observed.
CONCLUSIONS: Growth of a TG lesion contributed to PD in less than 50% of patients. PD from a NT and a new lesion were the most common criteria, with a significantly shorter PFS, despite being considered uncommon per R1.1.
